Bob

YalePublished by Yale University
Press. Click to learn more.

BN
Click to buy at
Barnes & Noble.com now!

amazon
Click to buy at
Amazon.com now!

280 p., 6 1/8 x 9 1/4
20 b/w illus.
ISBN: 9780300151022
ISBN-10: 0300151020

Media Links

Yale
Richard's YALE Blog

WebMD

Richard's WebMD Blog

Articles

Article in CURE Magazine on The Fragile Bonds of Cancer

Article in the Journal of Clnical Oncology on The Hardest Job in Medicine

Article in the Bottom Line Health Newsletter on Incurable Cancer

Wall Street Journal article on Cancer in the Elderly

NYT Letter on Taking Risks to Advance Public Health

NYT Letter on Deciding Where to Go for Cancer Care

NYT Science Times Letter on Accepting Hospice Care

Interviews

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Interview with American Society of Clinical Oncology (ASCO)

NPR Interview

An interview with CancerCare

An interview with The Healthy Aging Show

Book Reviews

Review from CURE Magazine

Review from India

Review in HemOnc Today

Reviews from Australia

SELF Magazine Recommended Book (NEW)

Review in Oncology Business Review

A chapter excerpt in "Coping with Cancer"

Blogged by Wendy Harpham, author/physician/cancer survivor

Awards

American Medical Writers Association, First Place
Medical Book Awards for 2010

American Medical Writers Association, 2010 Will Solimene
Award for Excellence in Medical Communication

Medical/Scientific Publications

Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

Response of carcinoma of unknown primary site affecting bone to thalidomide

Fetal microchimeric cells and breast cancer

Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins

The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.